Moderna stock surged after its personalized mRNA cancer vaccine produced positive late-stage trial results with Merck’s Keytruda. Marvell Technology shares gained as Google received a potential $12.2 billion…
Moderna stock surged after its personalized mRNA cancer vaccine produced positive late-stage trial results with Merck’s Keytruda. Marvell Technology shares gained as Google received a potential $12.2 billion…